Biologic Therapies in Atopic Dermatitis

CE / CME

Breaking Down Biologic Therapies in Moderate to Severe Atopic Dermatitis: Who, What, When, Why, and How?

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: December 02, 2024

Expiration: December 01, 2025

Sandri Johnson
Sandri Johnson, MSN, FNP-BC, DCNP
Jonathan Silverberg
Jonathan Silverberg, MD, PhD, MPH

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following best summarizes considerations for use of biologic agents in AD?

2.

Which of the following patients with moderate to severe AD would be the most appropriate candidate for biologic therapy?

3.

How often do you currently incorporate validated screening tools when choosing a therapy to treat AD?

4.

How often do you currently consider an agent’s mechanism of action when designing a plan to treat moderate to severe AD?